FDA Issues Serious Liver Injury Warning for Obeticholic Acid

The FDA has issued a warning of serious liver injury for patients taking obeticholic acid for primary biliary ...

DECEMBER 16, 2024

FDA Declines to Grant Full Approval to Obeticholic Acid for PBC

The FDA has declined to grant full approval to obeticholic acid (Ocaliva, Intercept) for the treatment of adults ...

NOVEMBER 14, 2024

MASH Therapy Pipeline Growing, With a Mix of Results

After years without drug treatments for metabolic dysfunction–associated steatohepatitis, recently data have ...

AUGUST 22, 2024

New Agents for NASH Show Promise for Disease Resolution

New data are supporting the use of novel agents in the treatment of NASH, according to late-breaking abstracts ...

MARCH 28, 2023

Obeticholic Acid Proves Its Mettle As Second-Line Therapy for PBC

Patients with primary biliary cholangitis treated with obeticholic acid as second-line therapy within the POISE ...

NOVEMBER 29, 2022

FDA Warns Providers About Prescribing Ocaliva in Patients With PBC and Advanced Cirrhosis

The FDA is warning physicians not to prescribe obeticholic acid (Ocaliva, Intercept) to patients with primary ...

MAY 27, 2021

Trial Results Mixed for Frontrunning NASH Therapy

For treatment of non-alcoholic steatohepatitis, obeticholic acid (OCA) met one of its primary end points but not ...

MARCH 13, 2020

FDA Adds Boxed Warning to Ocaliva Label to Highlight Correct Dosing

The FDA issued a Drug Safety Communication related to obeticholic acid (Ocaliva, Intercept), warning that the drug ...

FEBRUARY 2, 2018